Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation
DATE       2016-08-29
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT  |  DÉCLARATION

Choi J., et al. - Legalization of Marijuana

Health Canada’s Consultation on “Plain and Standardized Packaging”

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016

CMA

Dear Health Canada,

I am writing to respond to your consultation on “Plain and Standardized Packaging.” This consultation presents an important opportunity to improve the safety and accessibility of pharmaceuticals in Canada. As the President of the Canadian Medical Association (CMA), I am pleased to provide my organization’s perspective.

The CMA appreciates Health Canada’s efforts to address the issue of product safety and user-friendly packaging. We support initiatives that aim to reduce the risk of medication errors and improve patient outcomes. The CMA encourages the adoption of standardized packaging, as it can help prevent confusion and facilitate the safe and effective use of medications.

We applaud Health Canada’s approach to this consultation and appreciate the opportunity to provide feedback. The CMA supports the development of evidence-based guidelines to ensure that any changes to packaging are scientifically sound and benefit patients.

In conclusion, the CMA encourages Health Canada to continue its work in this area and to consider the input provided by stakeholders, including the CMA. We believe that standardized packaging is a critical step towards improving patient safety and public health in Canada.

Sincerely,

[Signature]

Chair, CMA

Canadian Medical Association
National pharmacare in Canada: Getting there from here

https://policybase.cma.ca/link/policy11959

POLICY TYPE
Parliamentary submission

DATE
2016-06-01

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE  Response to consultation
DATE  2016-03-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE          2016-01-20
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs
               Health care and patient safety

Documents